Initial experience with an everolimus-eluting, second-generation drug-eluting stent for treatment of intracranial atherosclerosis

Journal of NeuroInterventional Surgery

Volumn 2, Issue 2, 2010, Pages 104-109

  Natarajan, Sabareesh K ^a,b   Ogilvy, Christopher S ^a,b,c   Hopkins, L Nelson ^a,b   Siddiqui, Adnan H ^a,b   Levy, Elad I ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b Millard Fillmore Gates Circle Hospital   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BASILAR ARTERY; BRAIN ANGIOGRAPHY; BRAIN ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CLINICAL ARTICLE; COMORBIDITY; CORONARY ARTERY DISEASE; DECOMPRESSIVE CRANIECTOMY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG ELUTING STENT; ENDOVASCULAR SURGERY; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; INTERNAL CAROTID ARTERY; INTRACRANIAL ATHEROSCLEROTIC STENOSIS; MIDDLE CEREBRAL ARTERY; PETROUS INTERNAL CAROTID ARTERY; PRIORITY JOURNAL; RANKIN SCALE; RETROSPECTIVE STUDY; STROKE; SUPRACLINOID INTERNAL CAROTID ARTERY; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; AGED, 80 AND OVER; BALLOON DILATION; DRUG-ELUTING STENTS; FOLLOW-UP STUDIES; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME;

EID: 79960453209     PISSN: 17598478     EISSN: 17598486     Source Type: Journal    
DOI: 10.1136/jnis.2009.001875     Document Type: Article

References (46)

1. Gorelick PB, Wong KS, Bae HJ, et al. Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. Stroke 2008;39:2396-9.
2. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480-6.
3. Kasner SE, Chimowitz MI, Lynn MJ, et al. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006;113:555-63.
4. EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. N Engl J Med 1985;313:1191-200.
5. Levy EI, Turk AS, Albuquerque FC, et al. Wingspan in-stent restenosis and thrombosis: incidence, clinical presentation, and management. Neurosurgery 2007;61:644-51.
6. Albuquerque FC, Levy EI, Turk AS, et al. Angiographic patterns of Wingspan in-stent restenosis. Neurosurgery 2008;63:23-8.
7. Jiang WJ, Xu XT, Du B, et al. Comparison of elective stenting of severe vs moderate intracranial atherosclerotic stenosis. Neurology 2007;68:420-6. (Pubitemid 46208744)
8. SSYLVIA Study Investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke 2004;35:1388-92.
9. Turk AS, Levy EI, Albuquerque FC, et al. Influence of patient age and stenosis location on Wingspan in-stent restenosis. AJNR Am J Neuroradiol 2008;29:23-7.
10. Groschel K, Schnaudigel S, Pilgram SM, et al. A systematic review on outcome after stenting for intracranial atherosclerosis. Stroke 2009;40:e340-7.
11. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006;354:483-95. (Pubitemid 43200299)
12. Steinfort B, Ng PP, Faulder K, et al. Midterm outcomes of paclitaxel-eluting stents for the treatment of intracranial posterior circulation stenoses. J Neurosurg 2007;106:222-5. (Pubitemid 46203146)
13. Qureshi AI, Kirmani JF, Hussein HM, et al. Early and intermediate-term outcomes with drug-eluting stents in high-risk patients with symptomatic intracranial stenosis. Neurosurgery 2006;59:1044-51. (Pubitemid 44852090)
14. Abou-Chebl A, Bashir Q, Yadav JS. Drug-eluting stents for the treatment of intracranial atherosclerosis: initial experience and midterm angiographic follow-up. Stroke 2005;36:e165-8.
15. Lee SH, Jung JH, Shim WH. Endovascular treatment of basilar artery stenosis with drug-eluting stent: a case report and literature review. Catheter Cardiovasc Interv 2005;64:296-300. (Pubitemid 40322038)
16. Gupta R, Al-Ali F, Thomas AJ, et al. Safety, feasibility, and short-term follow-up of drug-eluting stent placement in the intracranial and extracranial circulation. Stroke 2006;37:2562-6. (Pubitemid 44454680)
17. Levy EI, Hanel RA, Tio FO, et al. Safety and pharmacokinetics of sirolimus-eluting stents in the canine cerebral vasculature: 180 day assessment. Neurosurgery 2006;59:925-34.
18. Levy EI, Hanel RA, Howington JU, et al. Sirolimus-eluting stents in the canine cerebral vasculature: a prospective, randomized, blinded assessment of safety and vessel response. J Neurosurg 2004;100:688-94. (Pubitemid 38372851)
19. Kukreja N, Onuma Y, Serruys PW. Xience V everolimus-eluting coronary stent. Expert Rev Med Devices 2009;6:219-29.
20. Carter AJ, Brodeur A, Collingwood R, et al. Experimental efficacy of an everolimus eluting cobalt chromium stent. Catheter Cardiovasc Interv 2006;68:97-103. (Pubitemid 44024469)
21. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008;52:333-42. (Pubitemid 352001347)
22. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942-7. (Pubitemid 38544483)
23. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80. (Pubitemid 34586912)
24. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23. (Pubitemid 37186209)
25. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9. (Pubitemid 37222332)
26. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-15. (Pubitemid 38352997)
27. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42. (Pubitemid 36070930)
28. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94. (Pubitemid 37022118)
29. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31. (Pubitemid 38067635)
30. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215-23. (Pubitemid 41352109)
31. Dawkins KD, Grube E, Guagliumi G, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005;112:3306-13. (Pubitemid 43739376)
32. Hill RA, Dundar Y, Bakhai A, et al. Drug-eluting stents: an early systematic review to inform policy. Eur Heart J 2004;25:902-19. (Pubitemid 38857864)
33. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008. (Pubitemid 46376800)
34. Kandzari DE, Roe MT, Ohman EM, et al. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol 2005;96:750-5. (Pubitemid 41317641)
35. O'Brien B, Carroll W. The evolution of cardiovascular stent materials and surfaces in response to clinical drivers: a review. Acta Biomater 2009;5:945-58.
36. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5. (Pubitemid 38222887)
37. Ellis SG, Colombo A, Grube E, et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol 2007;49:1043-51. (Pubitemid 46357591)
38. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91. (Pubitemid 44881238)
39. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006; 119:1056-61. (Pubitemid 44826931)
40. Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimuseluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 2009;119:680-6.
41. Biondi-Zoccai G, Lotrionte M, Moretti C, et al. Percutaneous coronary intervention with everolimus-eluting stents (Xience V): systematic review and direct-indirect comparison meta-analyses with paclitaxel-eluting stents (Taxus) and sirolimus-eluting stents (Cypher). Minerva Cardioangiol 2008;56:55-65. (Pubitemid 351522712)
42. Onuma Y, Kukreja N, Piazza N, et al. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. J Am Coll Cardiol 2009;54:269-76.
43. Moussa ID, Colombo A. Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers, reasons, and management recommendations. Catheter Cardiovasc Interv 2009;74:1047-54.
44. Nair R, Simon DI. Antiplatelet therapy in the era of late stent thrombosis. Curr Treat Options Cardiovasc Med 2008;10:12-17. (Pubitemid 351247768)
45. Bischof M, Briel M, Bucher HC, et al. Cost-effectiveness of drug-eluting stents in a US Medicare setting: a cost-utility analysis with 3-year clinical follow-up data. Value Health 2009. doi:10.1111/j.1524-4733.2009.00513.x.
46. Brunner-La Rocca HP, Kaiser C, Bernheim A, et al. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitats Trial (BASKET): an 18-month analysis. Lancet 2007;370:1552-9. (Pubitemid 350018894)